vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
France's oldest lighthouse is 'unique in the world' French News and Views in English
Pioneer launches Nissan Magnite - The Himalayan Times - Nepal's No.1 English Daily Newspaper
Conferences and exhibitions now allowed in MCO states, with limits on numbers
Activists calls for sanctions in wake of Myanmar coup
Lancashire LIVE: Bomb squad called after suspected hand grenade found in Blackpool
Humanitarian Coordinator calls for urgent support to Sudan
Salmon farmer SalMar ramps up offshore investments with new hire and possibility of international expansion
Braga, Nossa Senhora de Guadalupe, Campo Novo 360 Panorama
Photo shows glass turtle pendant, not ‘real tortoise living in Atlantic Ocean’
Imperative to revitalize China-US people-to-people exchanges
Taunton gasification plant proposed by Aries on site of old landfill
It's alive! Black-browed Babbler rediscovered after 170 years
15 PHOTOS: SS Rajamouli, Allu Arjun's family, Mahesh Babu, Jr NTR & other celebs papped at Sukumar's function
Malaysian island reclamation plan divides residents
Lancaster city to begin creating new comprehensive plan for community development
Martha and Michael Married At First Sight Australia: Where do Martha and Michael live?
Boston - Peace of Mind
Florida Man Pleads Guilty For His Role In Credit/Debit Card Scheme
Earth Hour 2021 shines a spotlight on the perilous state of the planet, calling for urgent action to set nature on the path of recovery.
Boris Johnson must be 'honest' with the public about need for austerity, Hammond says
Kenya: Monthly Injection to Replace Daily Pills for HIV Treatment
p A new HIV drug which could see patients stop taking daily antiretroviral therapy drugs has been approved by the US Food and Drug Administration.A total of 80 per cent of adults living with HIV in Kenya are aware of their diagnosis; 96 per cent of those aware of their diagnosis are on antiretroviral therapy (ART); and 91 per cent of those on treatment have achieved viral load suppression.The greenlight for the drug is based on the phase III ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) studies that included more than 1,100 patients from 16 countries.With 12 jabs annually, Cabenuva has been found to be effective in maintaining a viral suppression among adults living with HIV with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine.
According to the Kenya population-based HIV impact assessment (Kenphia) 2018 survey, there has been a steady increase in the number of people living with HIV who have been having access to life-long antiretroviral (ARV) drugs.The drug, known as Cabenuva (cabotegravir and rilpivirine) which is administered as an injection once a month, not only frees patients from taking pills everyday but also accords them privacy compared to the current antiretroviral (ARV) regimen.